Back to News
Market Impact: 0.2
Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
Source: proactiveinvestors.com
Healthcare & BiotechPatents & Intellectual Property
Poolbeg Pharma secured a South Korean patent for POLB 001 to prevent cytokine release syndrome induced by cancer immunotherapy. The patent covers a potential use addressing a serious complication, but the article provides no commercial or clinical outcome details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
POLB0.55
More News
- Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
- Why is Telix Pharmaceuticals stock rallying today?
- Netlist stock: why Micron will pay NLST $30M a quarter for 5 years
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD